
Press Release**DIASORIN INTRODUCES PRIMER PAIR REAGENTS FOR USE IN MOLECULAR TESTING: *ANAPLASMA PHAGOCYTOPHILUM*, *EHRlichIA* AND *BABESIA***

June 12th, 2018 - Saluggia (VC) - DiaSorin (FTSE Mid Cap: DIA) announced today the launch of three new primer pairs for use in laboratory-developed molecular tests.

The reagents are specific to three bacterial targets – *Anaplasma phagocytophilum*, *Ehrlichia* and *Babesia species*. These bacteria are commonly carried by ticks.

The new offerings join DiaSorin Molecular's menu of more than 60 molecular reagents for bacterial, viral and fungal targets in addition to human genetic mutations.

The primer pairs are classified as Analyte Specific Reagents (ASRs), which can be used by high-complexity laboratories to develop their own laboratory developed tests (LDTs).

Tick-borne infections are more than doubling between 2004 and 2016 mainly due to the increase in human travel, which can result in the spread of tick-borne bacteria to new locations, climate and habitat changes affecting animals that harbor ticks.

"These new primer pairs are the result of our ongoing work to develop and deliver a robust menu of molecular products," said Michelle Tabb, Vice president of research and development for DiaSorin Molecular. *"With greater access to commercially developed molecular reagents, diagnostic labs are better able to customize tests that meet their unique patient needs."*

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the "Diagnostic Specialist".

For additional information, please contact:**Riccardo Fava**

Investor Relations & Corporate Communication Senior Director

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Ines Di Terlizzi

Investor Relator

Tel: +39.0161.487567

ines.diterlizzi@diasorin.it